Jubilant Organosys, through its subsidiary Jubilant Biosys based in Bangalore announced that it’s four year old research collaboration with Eli Lilly & Company, has successfully delivered multiple discovery milestones and preclinical candidates, resulting in a five-year extension and an expanded portfolio collaboration.
Jubilant and Lilly had entered into an initial discovery research collaboration in late 2005. Lilly will continue to own any compounds developed under the collaboration and will be responsible for worldwide comercialisation.
Lilly and Jubilant had also established a joint venture, Vanthys Pharmaceuticals, for early stage drug development in 2008. Under the terms of the new five year agreement Jubilant will receive research funding and success- based discovery and development milestones.
